Safety of nasal budesonide in the long‐term treatment of children with perennial rhinitis

200381 citationsJournal Article

Authors

C. Møller · Umeå University

H Ahlström · Angelini Pharma (Italy)

Kent Åke Henricson · Halmstad University

Lasse Malmqvist · Centralsjukhuset Kristianstad

Anders Åkerlund · AstraZeneca (Brazil)

Hans Hildebrand · Karolinska Institutet

Abstract

Long-term treatment for 1-2 years with intranasal budesonide 256-400 microg daily in children with perennial rhinitis revealed no negative effects on growth or endogenous cortisol production. Local side-effects were mild and patient symptoms decreased.

Topics & Keywords

Allergic Rhinitis and Sensitization Asthma and respiratory diseases Nasal Surgery and Airway Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical & Experimental Allergy

Volume 33, Issue 6, pp. 816-822

DOI: 10.1046/j.1365-2222.2003.01689.x

Field-Weighted Citation Impact: 1.76